Assessing SSRIs' effects on fetal cardiomyocytes utilizing placenta-fetus model. (November 2019)

• Record Type: Journal Article
• Authors: Arumugasaamy, Navein; Hurley-Novatny, Amelia; Lembong, Josephine; Kim, Peter C.W.; Fisher, John P.
• Is Part Of: Acta biomaterialia. Volume 99(2019)
• Page Start: 258
• Page End: 268
• Publication Date: 2019-11
• Subjects: Placenta -- Placental barrier -- Tissue engineering -- Selective serotonin reuptake inhibitors -- Cardiomyocytes; Biomedical materials -- Periodicals; 610.28
• DOI: 10.1016/j.actbio.2019.09.019
• Languages: English
• ISSNs: 1742-7061

Abstract

Graphical abstract: Abstract: Selective serotonin reuptake inhibitors (SSRIs) have been shown to hinder cardiomyocyte signaling, raising concerns about their safety during pregnancy. Approaches to assess SSRI-induced effects on fetal cardiovascular cells following passage of drugs through the placental barrier in vitro have only recently become available. Herein, we report that the SSRIs, fluoxetine and sertraline, lead to slowed cardiomyocyte calcium oscillations and induce increased secretion of troponin T and creatine kinase-MB with reduced secretion of NT-proBNP, three key cardiac injury biomarkers. We show the cardiomyocyte calcium handling effects are further amplified following indirect exposure through a placental barrier model. These studies are the first to investigate the effects of placental barrier co-culture with cardiomyocytes in vitro and to show cardiotoxicity of SSRIs following passage through the placental barrier. Statement of Significance: Use of selective serotonin reuptake inhibitors (SSRIs), a class of antidepressants, during pregnancy continues to rise despite multiple studies showing potential for detrimental effects on the developing fetus. SSRIs are particularly thought to slow cardiovascular electrical activity, such as ion signaling, yet few, if any, methods exist to rigorously study these drug-induced effects on human pregnancy and the developing fetus. Within this study, we utilized a placenta-fetus model to evaluate these drug-induced effects on cardiomyocytes, looking the drugs' effects on calcium handling and secretion of multiple cardiac injury biomarkers. Together, with existing literature, this study provides a platform for assessing pharmacologic effects of drugs on cells mimicking the fetus and the role the placenta plays in this process.